Genetics Institute/Wyeth - IL-11 in Ankylosing Spondylitis Study

Comprises records relating to the phase I study "A Phase 1, Double Blind, Placebo-Controlled, Dose Escalating Study of Recombinant Human Interleukin-11 (rhIL-11) in Patients with Ankylosing Spondylitis."

The study was led by Principal Investigator Prof. Ravinder Maini on behalf of the Kennedy Institute in collaboration with sponsors the Genetics Institute and then later Wyeth-Ayerst Research. The study included multiple centres in EU countries, 3 cohorts of patients, 48 patients total, lasting a total 126 days. The purpose of the study was to assess the safety and activity of subcutaneous injection (under the skin) of rhIL-11 in patients with active Ankylosing Spondylitis. The study was terminated for safety in 2002.